Ardelyx (ARDX) Depreciation & Amortization (CF) (2013 - 2026)
Ardelyx (ARDX) reported Depreciation & Amortization (CF) of $915000.0 for Q1 2026, up 51.99% on a YoY basis from $602000.0 in Q1 2025, and down 0.65% quarter-over-quarter from $921000.0 in Q4 2025.
Ardelyx (ARDX) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Ardelyx has reported Depreciation & Amortization (CF) for 14 years, with the latest figure at $915000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 51.99% year-over-year to $915000.0; the trailing twelve-month figure through Mar 2026 stood at $3.4 million (up 51.21% YoY), and the FY2025 full-year result was $3.1 million, up 48.28% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $915000.0, down from $921000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $921000.0 in Q4 2025, with the low at -$3000.0 in Q1 2023.
- Historically, Depreciation & Amortization (CF) has averaged $498411.8 across 5 years, with a median of $515000.0 in 2024.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) plunged 100.65% — and 2024, when it soared 14600.0%.
- Ardelyx's Depreciation & Amortization (CF) stood at $127000.0 in 2022, then soared by 185.04% to $362000.0 in 2023, then surged by 42.27% to $515000.0 in 2024, then soared by 78.83% to $921000.0 in 2025, then declined by 0.65% to $915000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $915000.0 (Q1 2026), $921000.0 (Q4 2025), and $905000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | 915,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 915,000.00 |
| Mar 31, 2026 | 915,000.00 |
| Dec 31, 2025 | 921,000.00 |
| Dec 31, 2025 | 921,000.00 |
| Sep 30, 2025 | 905,000.00 |
| Sep 30, 2025 | 905,000.00 |
| Jun 30, 2025 | 631,000.00 |
| Jun 30, 2025 | 631,000.00 |
| Mar 31, 2025 | 602,000.00 |
| Mar 31, 2025 | 602,000.00 |
| Dec 31, 2024 | 515,000.00 |
| Dec 31, 2024 | 515,000.00 |
| Sep 30, 2024 | 544,000.00 |
| Sep 30, 2024 | 544,000.00 |
| Jun 30, 2024 | 569,000.00 |
| Jun 30, 2024 | 569,000.00 |
| Mar 31, 2024 | 435,000.00 |
| Mar 31, 2024 | 435,000.00 |
| Dec 31, 2023 | 362,000.00 |
| Dec 31, 2023 | 362,000.00 |